Obstructive Sleep Apnea Clinical Trial
Official title:
Non-Inferiority Study of the FRESCA Mask Versus Existing CPAP Mask for Treatment of Obstructive Sleep Apnea
Verified date | April 2018 |
Source | FRESCA Medical |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This will be a prospective study in subjects with Obstructive Sleep Apnea (OSA) to characterize the clinical performance during a single night of therapy with a FRESCA mask compared with a single night of therapy with their existing nasal Continuous Positive Airway Pressure (CPAP) mask.
Status | Completed |
Enrollment | 47 |
Est. completion date | October 2015 |
Est. primary completion date | September 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: 1. Male or Female 18-70 years old; 2. Qualifying diagnostic polysomnography (PSG): Resulting in AHI > 5/hr of sleep (using conventional lab or home test); 3. Qualifying titration PSG: In lab titration within the past 12 months and therapeutic pressure resulting in Apnea Hypopnea Index (AHI) < 5/hr; 4. Primary medical diagnosis of OSA/ Hypopnea syndrome and on CPAP treatment > 1 month; 5. Current user of nasal mask or nasal pillow mask; 6. Have regular usage of their CPAP machine ( at least 4 hrs per night and at least 5 nights per week) confirmed by secure digital (SD) card download; 7. No significant changes in the subject's general health and no change in weight greater than ±10 lbs since titration PSG was performed and CPAP therapy initiated (confirmed from medical records); 8. BMI < 35 kg/m2; 9. Must be able to be fit properly with FRESCA mask; 10. Must be able to comply with all study requirements as outlined in the protocol; 11. Must be able to understand English and be willing to provide written informed consent. Exclusion Criteria: 1. Subjects with non OSA sleep disorders; 2. Substantial central or mixed apneas (Central and Mixed apnea index = 5/hr); 3. Subjects actively using bi-level PAP or require oxygen therapy; 4. Subjects using a full face mask or chin strap; 5. History of severe cardiovascular disease, including New York Heart Association (NYHA) Class III or IV heart failure, coronary artery disease (CAD) with angina or myocardial infarction (MI)/stroke within past 6 months; 6. Subjects who are medically complicated or who are medically unstable (i.e. cancer, dementia, unstable cardiac or respiratory disease, or unstable psychiatric illness); 7. Potential sleep apnea complications that in the opinion of the investigator may affect the health and safety of the participant including: uncontrolled hypertension or hypotension, low blood oxygen (oxygen desaturations nadirs below 75% on their diagnostic PSG), or use of medication or other treatment which may pose additional risk to the subject; 8. Subjects exhibiting any flu-like or any upper airway tract infection symptoms at time of assessment; 9. Subjects with ongoing severe nasal allergies or sinusitis or difficulty breathing through the nose; persistent blockage or one or both nostrils; or any nasal or facial abnormalities that would not allow adequate placement of the device; 10. Subjects with prior surgical intervention for obstructive sleep hypopnea/ apnea syndrome; 11. Currently working nights, rotating night shifts, planned travel across two or more time zones required during study period, or within two weeks prior to study enrollment, or sleep schedule not compatible with sleep lab practices; 12. Unstable use of medications or other agents that may affect sleep or PSG (sedatives or hypnotics); 13. Pregnant (confirmed verbally); 14. Consumption of > 500mg caffeine per day (e.g. > 8 cola-type beverages, > 5 cups of coffee); 15. Currently enrolled in any other research study |
Country | Name | City | State |
---|---|---|---|
United States | SleepMed of South Carolina | Columbia | South Carolina |
United States | Sequoia Sleep Diagnostics | Fresno | California |
United States | Broward Research Group | Hollywood | Florida |
United States | Complete Sleep Solutions | Murrieta | California |
United States | CliniLabs, Inc | New York | New York |
Lead Sponsor | Collaborator |
---|---|
FRESCA Medical |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Apnea Hypopnea Index (AHI) | The Apnea-Hypopnea Index or Apnoea-Hypopnoea Index (AHI) is an index used to indicate the severity of sleep apnea. It is represented by the number of apnea and hypopnea events per hour of sleep. Difference of AHI values between patients who used the FRESCA treatment first versus the CPAP treatment. | per hour | |
Primary | Oxygen Desaturation Index (ODI) | The Oxygen Desaturation Index (ODI) is the number of times per hour of sleep that the blood's oxygen level drop by a certain degree from baseline. The ODI is typically measured as part of standard sleep studies, such as a diagnostic polysomnogram, home sleep apnea testing, or with overnight oximetry.Difference of ODI values between patients who used the FRESCA treatment first versus the CPAP treatment. | per hour | |
Secondary | Arousal Index (AI) | The number of arousals per hour; arousals are defined as a change in EEG for at least 3 seconds. | per hour | |
Secondary | Sleep Efficiency (SE%) | Sleep Efficiency (%) [100 x Total sleep time/ total recording time] reported per treatment | per night | |
Secondary | Minimum Sleep SpO2 (%) | The minimum O2 level percentage during treatment reported per treatment | per night | |
Secondary | Mean Sleep SpO2 -(%) | Mean Sleep SpO2 - blood oxygenation level (%) mean value reported per treatment | per night | |
Secondary | Wakefulness (Min) | Measure of time not sleeping (minutes) | per night | |
Secondary | Stage N1 (Min) | Stage N1 sleep is an estimate of the degree of sleep fragmentation. | per night | |
Secondary | Stage N2 (Min) | Stage N2 sleep predominates the sleep stages with 50% of the total sleep time. It follows the Stage N1 sleep and continues to recur throughout the night. | per night | |
Secondary | Stage N3 (Min) | Stage N3 is considered as 'deep sleep'. It is sometimes referred as slow wave sleep. | per night | |
Secondary | REM (Min) | The exact function of the REM is uncertain. However, it occupies approximately 25% of the total sleep time. REM sleep cycles occur every 90 to 120 min throughout the night with progressively increasing periods of time. REM sleep is associated with more frequent and longer duration apneas, hypopneas, and severe hypoxemia | per night |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05857384 -
Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs
|
Phase 1 | |
Recruiting |
NCT04547543 -
Follow-up of Apneic Patients by Visio-consultation
|
N/A | |
Recruiting |
NCT05371509 -
Novel Myofunctional Water Bottle to Reduce OSA and Snoring Study
|
N/A | |
Completed |
NCT02515357 -
Mediterranean Diet/Lifestyle Intervention in Obstructive Sleep Apnea
|
N/A | |
Completed |
NCT05582070 -
Effect on Sleep of Surgical Treatment of Severe Nasal Obstruction
|
N/A | |
Active, not recruiting |
NCT03189173 -
Combined Upper-airway and Breathing Control Therapies for Obstructive Sleep Apnea
|
Phase 2 | |
Completed |
NCT04084899 -
The Effect of CPAP on Lung Hyperinflation in Patients With OSA
|
||
Completed |
NCT03032029 -
Registry on the Treatment of Central and Complex Sleep-Disordered Breathing With Adaptive Servo-Ventilation
|
||
Recruiting |
NCT04028011 -
Clinical Evaluation of a Wearable Technology for the Diagnosis of Sleep Apnoea
|
||
Recruiting |
NCT06047353 -
Community Health Advocates for Motivating PAP Use in Our Neighborhoods.
|
N/A | |
Completed |
NCT05253963 -
Acute Effect of CPAP on Weight in Patients With Obstructive Sleep Apnea
|
N/A | |
Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
Recruiting |
NCT06150352 -
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
|
||
Completed |
NCT03589417 -
Postural Stability, Balance and Fall Risk in Patients With Obstructive Sleep Apnea
|
||
Recruiting |
NCT04335994 -
ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing
|
N/A | |
Withdrawn |
NCT04063436 -
Evaluation of a New Nasal Pillows Mask for the Treatment of Obstructive Sleep Apnea
|
N/A | |
Recruiting |
NCT05385302 -
Sociological Determinants of Positive Airway Pressure Adherence in OSA Patients
|
||
Recruiting |
NCT04572269 -
Metabolomics of Obstructive Sleep Apnea
|
||
Not yet recruiting |
NCT06467682 -
12-week Tele-exercise Program in Patients With OSA
|
N/A | |
Withdrawn |
NCT04011358 -
Retinal Vein Occlusion and Obstructive Sleep Apnea: A Case Control Study
|
N/A |